VeraSci’s eCOA ‘evolution’ to provide data ready for submission

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/flamingoimages)
(Image: Getty/flamingoimages)

Related tags: Clinical data, Clinical operations, clinical study, Clinical trial, Data collection, Data management

VeraSci is enhancing its eCOA platform to improve the participant experience, data collection, and consistency.

The electronic clinical outcome assessment (eCOA) platform will now offer boosted data collection and administration as well as access to greater types of scales and assessments.

The enhancements come after raters, scale-developers, and sponsors tested VeraSci’s eCOA platform, Pathway, to ensure it provides functionality while still accommodating each study and site.

Using a Pathway-enabled device, VeraSci’s proprietary assessments, endpoints, and safety measures for different therapeutic areas are now accessible. Raters can also now administer assessments on Pathway and obtain consent with the same device.

A spokesperson for the company told us that having clinical, cognitive, functional, and safety assessments accessible to sponsors on one device can ease logistics for both sites and subjects. The spokesperson said, “We design our tools in a way that streamlines data collection and allows technology to act as an aid to the clinician while not being a distraction to the participant. An improved participant experience leads to faster trial visits, faster data collection, and increased data accuracy.”

The platform can be used on a single device for multiple assessments and protocols. High enrollment sites can use different devices for parallel assessments of multiple patients through the platform as well.

“Real-time interactive data consistency checks promote more accurate source data and fewer requirements for data cleaning. Provision of intricate scoring guidelines to reference within the assessment eases the process of scoring, especially for new raters, creating a better experience for both clinician and study participants,” ​the spokesperson explained.

The spokesperson further explained that the algorithms VeraSci uses can provide additional guidance for data consistency. “New PANSS [Pathway] algorithms prevent rater errors and allow for conditional data entry, immediate notification, and safety flags.”

The platform is also available in multiple languages to accommodate sites located in different countries.

The evolution of Pathway is really about saving sponsors costs as well as allowing them to have access to the most accurate data in real-time while being ready for submission immediately after the last study participant is out,” ​the company spokesperson added.

 

Related news

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars